Celcuity Inc. (NASDAQ:CELC) Receives Average Rating of “Buy” from Analysts

Celcuity Inc. (NASDAQ:CELC) has been given a consensus recommendation of “Buy” by the six brokerages that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $29.00.

A number of research analysts have recently issued reports on CELC shares. Craig Hallum reiterated a “buy” rating and set a $27.00 target price (up previously from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a report on Thursday, August 15th. Stifel Nicolaus cut their price target on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Leerink Partnrs raised Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a report on Thursday, August 15th.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC purchased a new stake in Celcuity during the 4th quarter worth about $21,583,000. Baker BROS. Advisors LP lifted its position in Celcuity by 189.9% in the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after acquiring an additional 1,017,000 shares during the last quarter. Samlyn Capital LLC grew its holdings in shares of Celcuity by 92.4% during the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after purchasing an additional 637,190 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Celcuity in the 1st quarter valued at about $3,545,000. Finally, Driehaus Capital Management LLC grew its stake in Celcuity by 62.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock worth $3,351,000 after buying an additional 78,525 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Trading Down 0.3 %

Shares of NASDAQ:CELC opened at $16.99 on Friday. The company has a quick ratio of 11.23, a current ratio of 11.23 and a debt-to-equity ratio of 0.28. Celcuity has a 52-week low of $8.39 and a 52-week high of $22.19. The business has a 50-day moving average price of $16.85 and a 200-day moving average price of $16.87. The stock has a market cap of $596.37 million, a price-to-earnings ratio of -6.11 and a beta of 0.81.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. During the same period in the previous year, the company posted ($0.66) earnings per share. Equities analysts predict that Celcuity will post -2.86 EPS for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.